ReviewFrontiers in endocrinology2018
Fatherhood and Sperm DNA Damage in Testicular Cancer Patients.
Review in Frontiers in endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radioactive iodine and male reproductive health in thyroid cancer survivors: evidence of delayed gonadal dysfunction.Journal of endocrinological investigation · 2026Pooled it
- Before Orchiectomy: Gonadal Function in Testicular Germ Cell Tumors-A Narrative Review.Journal of clinical medicine · 2026Review
- Article
- Declining semen quality in North Africa: from 2019 to 2024: retrospective multicentric study of 21,585 patients.Reproduction & fertility · 2026Article
- Prostate Cancer Treatments and Their Effects on Male Fertility: Mechanisms and Mitigation Strategies.Journal of personalized medicine · 2025Review
- Exploring the therapeutic effect of melatonin targeting common biomarkers in testicular germ cell tumor, prostate adenocarcinoma, and male infertility: an integrated biology approach.Mammalian genome : official journal of the International Mammalian Genome Society · 2025Article
- Engineered nanoparticles potentials in male reproduction.Andrology · 2025Review
- Plant-derived extracellular vesicles: an alternative and complementary therapeutic approach for genitourinary tumors.Frontiers in cell and developmental biology · 2025Review
- The Smoky Impact of Nicotinic Acetylcholine Receptors on Testicular Function.Journal of clinical medicine · 2024Review
- Testicular and Haematological Cancer Induce Very High Levels of Sperm Oxidative Stress.Antioxidants (Basel, Switzerland) · 2023Article
- Bladder Neck Obstruction: Experience and Management in a Sperm Bank.Life (Basel, Switzerland) · 2023Article
- The Effects of Glutathione on Clinically Essential Fertility Parameters in a Bleomycin Etoposide Cisplatin Chemotherapy Model.Life (Basel, Switzerland) · 2023Article
- Cryopreservation of Human Spermatozoa: Functional, Molecular and Clinical Aspects.International journal of molecular sciences · 2023Review
- Sperm DNA Fragmentation and Sperm-Borne miRNAs: Molecular Biomarkers of Embryo Development?International journal of molecular sciences · 2023Article
- The impact of male factors and their correct and early diagnosis in the infertile couple's pathway: 2021 perspectives.Journal of endocrinological investigation · 2022Review
- Oleuropein Counteracts Both the Proliferation and Migration of Intra- and Extragonadal Seminoma Cells.Nutrients · 2022Article
- DNA damage in preimplantation embryos and gametes: specification, clinical relevance and repair strategies.Human reproduction update · 2022Review
- Management of male factor infertility: position statement from the Italian Society of Andrology and Sexual Medicine (SIAMS) : Endorsing Organization: Italian Society of Embryology, Reproduction, and Research (SIERR).Journal of endocrinological investigation · 2022Article
- Patient Reported Outcomes, Paternity, Relationship, and Fertility in Testicular Cancer Survivors: Results from a Prospective Observational Single Institution Trial.Patient preference and adherence · 2022Article
- Male infertility due to testicular disorders.The Journal of clinical endocrinology and metabolism · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Testicular cancer (TC) is one of the most treatable of all malignancies and the management of the quality of life of these patients is increasingly important, especially with regard to their sexuality and fertility. Survivors must overcome anxiety and fears about reduced fertility and possible pregnancy-related risks as well as health effects in offspring. There is thus a growing awareness of the need for reproductive counseling of cancer survivors. Studies found a high level of sperm DNA damage in TC patients in comparison with healthy, fertile controls, but no significant difference between these patients and infertile patients. Sperm DNA alterations due to cancer treatment persist from 2 to 5 years after the end of the treatment and may be influenced by both the type of therapy and the stage of the disease. Population studies reported a slightly reduced overall fertility of TC survivors and a more frequent use of ART than the general population, with a success rate of around 50%. Paternity after a diagnosis of cancer is an important issue and reproductive potential is becoming a major quality of life factor. Sperm chromatin instability associated with genome instability is the most important reproductive side effect related to the malignancy or its treatment. Studies investigating the magnitude of this damage could have a considerable translational importance in the management of cancer patients, as they could identify the time needed for the germ cell line to repair nuclear damage and thus produce gametes with a reduced risk for the offspring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.